LBX Pharmacy Chain（603883）株式概要LBX Pharmacy Chain Joint Stock Company は中国本土で薬局チェーンを展開している。 詳細603883 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性4/6配当金5/6報酬当社が推定した公正価値より43.6%で取引されている 収益は年間22.8%増加すると予測されています リスク分析不安定な配当実績 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る603883 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,204 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA488,204 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥12.568.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture034b2016201920222025202620282031Revenue CN¥33.9bEarnings CN¥601.8mAdvancedSet Fair ValueView all narrativesLBX Pharmacy Chain Joint Stock Company 競合他社Yixintang Pharmaceutical GroupSymbol: SZSE:002727Market cap: CN¥6.5bShuYu Civilian PharmacySymbol: SZSE:301017Market cap: CN¥5.6bDaShenLin Pharmaceutical GroupSymbol: SHSE:603233Market cap: CN¥20.8bAnhui Huaren Health PharmaceuticalSymbol: SZSE:301408Market cap: CN¥5.9b価格と性能株価の高値、安値、推移の概要LBX Pharmacy Chain過去の株価現在の株価CN¥12.5652週高値CN¥19.2352週安値CN¥10.67ベータ0.431ヶ月の変化7.44%3ヶ月変化-9.18%1年変化-32.83%3年間の変化-43.44%5年間の変化-57.03%IPOからの変化25.76%最新ニュースDeclared Dividend • Jul 01Dividend increased to CN¥0.27Dividend of CN¥0.27 is 238% higher than last year. Ex-date: 3rd July 2026 Payment date: 3rd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (79% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 87% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2026 Results on Aug 28, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2026 results on Aug 28, 2026お知らせ • May 28LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan ChinaPrice Target Changed • Apr 30Price target decreased by 8.4% to CN¥18.00Down from CN¥19.64, the current price target is an average from 10 analysts. New target price is 29% above last closing price of CN¥14.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.50 last year.Major Estimate Revision • Apr 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥24.5b to CN¥23.9b. EPS estimate also fell from CN¥1.06 per share to CN¥0.931 per share. Net income forecast to grow 88% next year vs 18% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥19.64 to CN¥18.70. Share price rose 2.8% to CN¥14.11 over the past week.Reported Earnings • Apr 23First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.33 in 1Q 2025). Revenue: CN¥5.48b (flat on 1Q 2025). Net income: CN¥263.9m (up 5.3% from 1Q 2025). Profit margin: 4.8% (up from 4.6% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 58%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesDeclared Dividend • Jul 01Dividend increased to CN¥0.27Dividend of CN¥0.27 is 238% higher than last year. Ex-date: 3rd July 2026 Payment date: 3rd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (79% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 87% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2026 Results on Aug 28, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2026 results on Aug 28, 2026お知らせ • May 28LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan ChinaPrice Target Changed • Apr 30Price target decreased by 8.4% to CN¥18.00Down from CN¥19.64, the current price target is an average from 10 analysts. New target price is 29% above last closing price of CN¥14.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.50 last year.Major Estimate Revision • Apr 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥24.5b to CN¥23.9b. EPS estimate also fell from CN¥1.06 per share to CN¥0.931 per share. Net income forecast to grow 88% next year vs 18% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥19.64 to CN¥18.70. Share price rose 2.8% to CN¥14.11 over the past week.Reported Earnings • Apr 23First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.33 in 1Q 2025). Revenue: CN¥5.48b (flat on 1Q 2025). Net income: CN¥263.9m (up 5.3% from 1Q 2025). Profit margin: 4.8% (up from 4.6% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 58%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.お知らせ • Mar 30LBX Pharmacy Chain Joint Stock Company to Report Q1, 2026 Results on Apr 23, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2026 results on Apr 23, 2026Buy Or Sell Opportunity • Feb 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥15.06. The fair value is estimated to be CN¥19.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 20%. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 25% per annum over the same time period.お知らせ • Dec 26LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2025 Results on Apr 23, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2025 results on Apr 23, 2026Reported Earnings • Oct 29Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: EPS: CN¥0.18 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥5.30b (flat on 3Q 2024). Net income: CN¥130.8m (up 2.6% from 3Q 2024). Profit margin: 2.5% (up from 2.4% in 3Q 2024). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 9.1%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 17% per year.お知らせ • Sep 30LBX Pharmacy Chain Joint Stock Company to Report Q3, 2025 Results on Oct 29, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2025 results on Oct 29, 2025Major Estimate Revision • Aug 27Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥23.6b to CN¥22.5b. EPS estimate also fell from CN¥1.08 per share to CN¥0.961 per share. Net income forecast to grow 73% next year vs 60% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥23.04 to CN¥22.26. Share price fell 2.9% to CN¥18.18 over the past week.Major Estimate Revision • Jul 11Consensus revenue estimates decrease by 11%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥23.6b to CN¥21.0b. EPS estimate increased from CN¥1.05 to CN¥1.08 per share. Net income forecast to grow 68% next year vs 68% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥23.77. Share price fell 3.7% to CN¥19.34 over the past week.New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (2.0% net profit margin).お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2025 Results on Aug 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2025 results on Aug 30, 2025お知らせ • Jun 09LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan ChinaReported Earnings • May 01Full year 2024 earnings released: EPS: CN¥0.68 (vs CN¥1.22 in FY 2023)Full year 2024 results: EPS: CN¥0.68 (down from CN¥1.22 in FY 2023). Revenue: CN¥22.4b (flat on FY 2023). Net income: CN¥519.1m (down 44% from FY 2023). Profit margin: 2.3% (down from 4.1% in FY 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.お知らせ • Mar 28LBX Pharmacy Chain Joint Stock Company to Report Q1, 2025 Results on Apr 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2025 results on Apr 30, 2025Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥19.24, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 4.4% over the past three years.お知らせ • Dec 27LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2024 results on Apr 30, 2025分析記事 • Dec 24Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Major Estimate Revision • Dec 10Consensus EPS estimates increase by 13%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.17 to CN¥1.31. Revenue forecast steady at CN¥22.8b. Net income forecast to grow 23% next year vs 44% growth forecast for Consumer Retailing industry in China. Consensus price target up from CN¥25.50 to CN¥26.24. Share price was steady at CN¥18.98 over the past week.分析記事 • Nov 06We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster EarningsLBX Pharmacy Chain Joint Stock Company's ( SHSE:603883 ) stock was strong despite it releasing a soft earnings report...Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥19.25, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 23% over the past three years.Reported Earnings • Oct 30Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.26 in 3Q 2023). Revenue: CN¥5.29b (up 1.2% from 3Q 2023). Net income: CN¥127.4m (down 37% from 3Q 2023). Profit margin: 2.4% (down from 3.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Upcoming Dividend • Oct 03Upcoming dividend of CN¥0.33 per shareEligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.9%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.9%).お知らせ • Sep 30LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2024 results on Oct 30, 2024Price Target Changed • Sep 20Price target decreased by 12% to CN¥26.64Down from CN¥30.14, the current price target is an average from 11 analysts. New target price is 88% above last closing price of CN¥14.18. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥1.43 for next year compared to CN¥1.22 last year.Valuation Update With 7 Day Price Move • Sep 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥13.28, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Consumer Retailing industry in China. Total loss to shareholders of 48% over the past three years.Major Estimate Revision • Sep 07Consensus EPS estimates fall by 29%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥26.0b to CN¥23.6b. EPS estimate also fell from CN¥2.08 per share to CN¥1.49 per share. Net income forecast to grow 6.3% next year vs 56% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥31.93 to CN¥30.14. Share price rose 33% to CN¥17.92 over the past week.分析記事 • Sep 06LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%LBX Pharmacy Chain Joint Stock Company ( SHSE:603883 ) shareholders are no doubt pleased to see that the share price...New Risk • Sep 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change).Valuation Update With 7 Day Price Move • Sep 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Consumer Retailing industry in China. Total loss to shareholders of 46% over the past three years.Buy Or Sell Opportunity • Sep 02Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 53% to CN¥12.24. The fair value is estimated to be CN¥15.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 9.8%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.分析記事 • Sep 02Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Jul 03Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% CheaperThe LBX Pharmacy Chain Joint Stock Company ( SHSE:603883 ) share price has fared very poorly over the last month...Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥18.36, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 17x in the Consumer Retailing industry in China. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.59 per share.お知らせ • Jun 28LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2024 results on Aug 30, 2024Declared Dividend • Jun 23Dividend increased to CN¥0.66Dividend of CN¥0.66 is 32% higher than last year. Ex-date: 27th June 2024 Payment date: 27th June 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 19% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 65% over the next 3 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Jun 08Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...お知らせ • May 24LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024, at 14:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China分析記事 • May 21LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Apr 30Full year 2023 earnings: EPS in line with expectations, revenues disappointFull year 2023 results: EPS: CN¥1.59 (up from CN¥1.36 in FY 2022). Revenue: CN¥22.4b (up 11% from FY 2022). Net income: CN¥929.0m (up 18% from FY 2022). Profit margin: 4.1% (up from 3.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.分析記事 • Apr 22There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is UndemandingLBX Pharmacy Chain Joint Stock Company's ( SHSE:603883 ) price-to-earnings (or "P/E") ratio of 20.9x might make it look...お知らせ • Mar 29LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2024 results on Apr 30, 2024Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥31.93, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Consumer Retailing industry in China. Total loss to shareholders of 45% over the past three years.お知らせ • Dec 29LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2023 results on Apr 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.26 in 3Q 2022). Revenue: CN¥5.23b (up 9.3% from 3Q 2022). Net income: CN¥203.3m (up 33% from 3Q 2022). Profit margin: 3.9% (up from 3.2% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 05Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: CN¥0.38. Revenue: CN¥5.37b (up 11% from 2Q 2022). Net income: CN¥221.9m (up 3.4% from 2Q 2022). Profit margin: 4.1% (down from 4.4% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China.Reported Earnings • Apr 29Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)Full year 2022 results: EPS: CN¥1.36 (up from CN¥1.26 in FY 2021). Revenue: CN¥20.2b (up 28% from FY 2021). Net income: CN¥785.0m (up 17% from FY 2021). Profit margin: 3.9% (down from 4.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Buying Opportunity • Apr 19Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.Price Target Changed • Apr 03Price target increased by 8.1% to CN¥45.36Up from CN¥41.97, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CN¥34.65. Stock is up 24% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year.Buying Opportunity • Apr 03Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 44% in 2 years. Earnings is forecast to grow by 52% in the next 2 years.Price Target Changed • Feb 03Price target increased by 7.5% to CN¥43.11Up from CN¥40.10, the current price target is an average from 7 analysts. New target price is 12% above last closing price of CN¥38.45. Stock is up 18% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year.Price Target Changed • Jan 14Price target increased to CN¥41.97Up from CN¥39.10, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of CN¥42.00. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥1.39 for next year compared to CN¥1.26 last year.Buying Opportunity • Dec 22Now 22% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be CN¥48.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 43% in 2 years. Earnings is forecast to grow by 51% in the next 2 years.Buying Opportunity • Dec 06Now 21% undervaluedOver the last 90 days, the stock is up 28%. The fair value is estimated to be CN¥52.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 42% in 2 years. Earnings is forecast to grow by 51% in the next 2 years.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Lianfeng Wu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2021). Revenue: CN¥4.79b (up 25% from 3Q 2021). Net income: CN¥153.1m (up 21% from 3Q 2021). Profit margin: 3.2% (down from 3.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 29Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥33.36, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total loss to shareholders of 21% over the past three years.Price Target Changed • May 21Price target decreased to CN¥58.58Down from CN¥63.49, the current price target is an average from 11 analysts. New target price is 61% above last closing price of CN¥36.32. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥1.86 for next year compared to CN¥1.64 last year.Major Estimate Revision • May 05Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥19.5b to CN¥18.5b. EPS estimate also fell from CN¥2.04 per share to CN¥1.61 per share. Net income forecast to grow 21% next year vs 30% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥63.49 to CN¥59.92. Share price rose 10.0% to CN¥32.24 over the past week.Reported Earnings • Apr 30First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: CN¥0.53. Revenue: CN¥4.14b (up 14% from 1Q 2021). Net income: CN¥241.8m (up 6.3% from 1Q 2021). Profit margin: 5.8% (down from 6.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 22%, compared to a 16% growth forecast for the industry in China.Price Target Changed • Apr 27Price target decreased to CN¥63.49Down from CN¥81.75, the current price target is an average from 8 analysts. New target price is 112% above last closing price of CN¥29.90. Stock is down 47% over the past year. The company is forecast to post earnings per share of CN¥1.70 for next year compared to CN¥1.54 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Yang Haiyu was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥3.82b (up 11% from 3Q 2020). Net income: CN¥126.8m (down 16% from 3Q 2020). Profit margin: 3.3% (down from 4.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 26LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion on August 24, 2021. Under the terms of consideration, The first advance payment: within 7 working days after this agreement is signed and effective, 20% of the total transfer price shall be paid, totaling CNY 285.6 million and The second transfer price: After the completion of the target company’s assets divestiture, the target equity change, the establishment of the target company’s board of directors, and the completion of the above work within seven working days, 40% of the total transfer price shall be paid, totaling CNY 571.2 million and The third transfer payment: 10% of the total transfer price shall be paid within 7 working days after the establishment of the board of directors, totaling CNY 142.8 million and The fourth transfer price: within 7 working days after the seller provides the personal income tax payment voucher, 10% of the total transfer price shall be paid, totaling CNY 142.8 million and The fifth transfer price: After auditing, evaluating and confirming that the net assets of the target company meet stipulated in this agreement on the delivery date, within 7 working days 10% of the total transfer price shall be paid, totaling RMB 142.8 million and The sixth transfer price: the amount of CNY 142.8 million yuan is the deposit, and the guarantee period is one year (calculated from the delivery date). After the expiration, the two parties confirm that the seller has no deductions for payment and shall pay within 7 working days. The consideration will be funded through its own funds. Hebei Hua Tuo Pharmacy Medicine Chain reported total assets of CNY 821.6 million and total common equity of CNY 227.7 million till April 31, 2021. LBX Pharmacy Chain Joint Stock Company's board approved the deal.Price Target Changed • Aug 20Price target decreased to CN¥75.25Down from CN¥81.75, the current price target is an average from 7 analysts. New target price is 53% above last closing price of CN¥49.27. Stock is down 36% over the past year.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.82b (up 12% from 2Q 2020). Net income: CN¥178.3m (up 28% from 2Q 2020). Profit margin: 4.7% (up from 4.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Price Target Changed • Aug 14Price target decreased to CN¥79.67Down from CN¥86.50, the current price target is an average from 6 analysts. New target price is 65% above last closing price of CN¥48.28. Stock is down 31% over the past year.Price Target Changed • Jun 16Price target decreased to CN¥86.50Down from CN¥93.56, the current price target is an average from 7 analysts. New target price is 61% above last closing price of CN¥53.65. Stock is down 20% over the past year.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.64b (up 11% from 1Q 2020). Net income: CN¥227.5m (up 16% from 1Q 2020). Profit margin: 6.3% (up from 6.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 09New 90-day low: CN¥61.85The company is down 10.0% from its price of CN¥68.36 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥48.82 per share.お知らせ • Feb 09Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership).Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) entered into an agreement to acquire Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) for CNY 680 million on December 18, 2020. As part of the transaction, Laobaixing Pharmacy Chain will pay CNY 20.4 million, CNY 20.6 million and CNY 27 million to Shanghai Chengzhen Enterprise Management Partnership, Shanghai Boyi Enterprise Management Consulting Service and Shanghai Xinzhen Marketing Planning Service Center, respectively. Laobaixing Pharmacy Chain will pay CNY 136 million within 7 working days after the signing of this agreement, CNY 476 million within seven working days after the completion of the settlement and the balance of CNY 68 million within seven working days of the settlement of related party's corresponding borrowings. The Board of Directors of Laobaixing Pharmacy Chain approved the transaction and no need to submit it to the general meeting of shareholders for review. Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) on February 8, 2020. Laobaixing Pharmacy Chain used own funds of CNY 680 million to acquire Jinan Xincheng Enterprise Management.Is New 90 Day High Low • Jan 13New 90-day high: CN¥81.64The company is up 1.0% from its price of CN¥80.70 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥78.46, the stock is trading at a trailing P/E ratio of 53.3x, up from the previous P/E ratio of 45.3x. This compares to an average P/E of 32x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 84%.Is New 90 Day High Low • Dec 28New 90-day low: CN¥63.60The company is down 22% from its price of CN¥81.13 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.Is New 90 Day High Low • Dec 12New 90-day low: CN¥65.89The company is down 19% from its price of CN¥81.54 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.Is New 90 Day High Low • Nov 18New 90-day low: CN¥67.21The company is down 8.0% from its price of CN¥73.07 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥53.67 per share.Price Target Changed • Nov 18Price target raised to CN¥97.98Up from CN¥89.75, the current price target is an average from 8 analysts. The new target price is 46% above the current share price of CN¥67.21. As of last close, the stock is up 33% over the past year.お知らせ • Nov 05Laobaixing Reportedly in Merger Talks with YixintangLaobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) and Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) are in advanced talks to create China’s biggest drugstore chain via a share swap, three people familiar with the matter said. Laobaixing’s founders, Xie Zilong and Chen Xiulan, are expected to have a bigger stake in the merged firm than Yixintang’s founder Ruan Hongxian, said two of the people. The talks have been ongoing for more than three months, the two people said. One person said the firms are aiming to finalize and announce the deal in the coming days, adding that Laobaixing would remain the listed entity. The sources declined to be identified as the discussions were not public. Laobaixing, Yixintang did not immediately respond to requests for comment yesterday.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥601.8m, up 19% from the prior year. Total revenue was CN¥13.4b over the last 12 months, up 21% from the prior year.お知らせ • Oct 30Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020Laobaixing Pharmacy Chain Joint Stock Company announced that they will report Q3, 2020 results on Oct 30, 2020お知らせ • Jul 09Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020Laobaixing Pharmacy Chain Joint Stock Company announced that they will report first half, 2020 results on Aug 21, 2020株主還元603883CN Consumer RetailingCN 市場7D0.08%4.2%2.6%1Y-32.8%-16.5%9.2%株主還元を見る業界別リターン: 603883過去 1 年間で-16.5 % の収益を上げたCN Consumer Retailing業界を下回りました。リターン対市場: 603883は、過去 1 年間で9.2 % のリターンを上げたCN市場を下回りました。価格変動Is 603883's price volatile compared to industry and market?603883 volatility603883 Average Weekly Movement4.2%Consumer Retailing Industry Average Movement5.8%Market Average Movement7.4%10% most volatile stocks in CN Market12.6%10% least volatile stocks in CN Market4.4%安定した株価: 603883 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 603883の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200136,892Zilong Xiewww.lbxdrugs.comLBX Pharmacy Chain Joint Stock Company は中国本土で薬局チェーンを展開している。同社は3つのセグメントで事業を展開している：小売事業、卸売事業、その他。日用品小売・卸売事業、医薬品製造事業などを行い、販売ネットワークを通じて医薬品やその他の健康・美容関連商品を販売している。また、医薬品の卸・小売事業、漢方薬の研究開発事業、Eコマース事業、食品・百貨店小売事業、日用品卸売事業、母子用品小売事業なども行っている。さらに、ビジネス、情報技術コンサルティング、技術、医薬コンサルティング、クリニック、医療サービスも提供している。同社の前身はLaobaixing Pharmacy Chain Joint Stock Company。LBX Pharmacy Chain Joint Stock Company は2001年に設立され、中国の長沙に本社を置く。もっと見るLBX Pharmacy Chain Joint Stock Company 基礎のまとめLBX Pharmacy Chain の収益と売上を時価総額と比較するとどうか。603883 基礎統計学時価総額CN¥9.53b収益（TTM）CN¥395.07m売上高(TTM)CN¥22.28b24.1xPER（株価収益率0.4xP/Sレシオ603883 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計603883 損益計算書（TTM）収益CN¥22.28b売上原価CN¥15.13b売上総利益CN¥7.15bその他の費用CN¥6.75b収益CN¥395.07m直近の収益報告Mar 31, 2026次回決算日Aug 28, 2026一株当たり利益（EPS）0.52グロス・マージン32.09%純利益率1.77%有利子負債／自己資本比率43.7%603883 の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.3%現在の配当利回り79%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 20:19終値2026/08/05 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LBX Pharmacy Chain Joint Stock Company 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19 アナリスト機関null nullChina International Capital Corporation LimitedQianyi LiChina International Capital Corporation LimitedBing ZhaoChina Renaissance Securities16 その他のアナリストを表示
Declared Dividend • Jul 01Dividend increased to CN¥0.27Dividend of CN¥0.27 is 238% higher than last year. Ex-date: 3rd July 2026 Payment date: 3rd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (79% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 87% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2026 Results on Aug 28, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2026 results on Aug 28, 2026
お知らせ • May 28LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China
Price Target Changed • Apr 30Price target decreased by 8.4% to CN¥18.00Down from CN¥19.64, the current price target is an average from 10 analysts. New target price is 29% above last closing price of CN¥14.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.50 last year.
Major Estimate Revision • Apr 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥24.5b to CN¥23.9b. EPS estimate also fell from CN¥1.06 per share to CN¥0.931 per share. Net income forecast to grow 88% next year vs 18% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥19.64 to CN¥18.70. Share price rose 2.8% to CN¥14.11 over the past week.
Reported Earnings • Apr 23First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.33 in 1Q 2025). Revenue: CN¥5.48b (flat on 1Q 2025). Net income: CN¥263.9m (up 5.3% from 1Q 2025). Profit margin: 4.8% (up from 4.6% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 58%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
Declared Dividend • Jul 01Dividend increased to CN¥0.27Dividend of CN¥0.27 is 238% higher than last year. Ex-date: 3rd July 2026 Payment date: 3rd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (79% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 87% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2026 Results on Aug 28, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2026 results on Aug 28, 2026
お知らせ • May 28LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China
Price Target Changed • Apr 30Price target decreased by 8.4% to CN¥18.00Down from CN¥19.64, the current price target is an average from 10 analysts. New target price is 29% above last closing price of CN¥14.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.50 last year.
Major Estimate Revision • Apr 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥24.5b to CN¥23.9b. EPS estimate also fell from CN¥1.06 per share to CN¥0.931 per share. Net income forecast to grow 88% next year vs 18% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥19.64 to CN¥18.70. Share price rose 2.8% to CN¥14.11 over the past week.
Reported Earnings • Apr 23First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.33 in 1Q 2025). Revenue: CN¥5.48b (flat on 1Q 2025). Net income: CN¥263.9m (up 5.3% from 1Q 2025). Profit margin: 4.8% (up from 4.6% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 58%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 30LBX Pharmacy Chain Joint Stock Company to Report Q1, 2026 Results on Apr 23, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2026 results on Apr 23, 2026
Buy Or Sell Opportunity • Feb 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥15.06. The fair value is estimated to be CN¥19.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 20%. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 25% per annum over the same time period.
お知らせ • Dec 26LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2025 Results on Apr 23, 2026LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2025 results on Apr 23, 2026
Reported Earnings • Oct 29Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: EPS: CN¥0.18 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥5.30b (flat on 3Q 2024). Net income: CN¥130.8m (up 2.6% from 3Q 2024). Profit margin: 2.5% (up from 2.4% in 3Q 2024). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 9.1%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 17% per year.
お知らせ • Sep 30LBX Pharmacy Chain Joint Stock Company to Report Q3, 2025 Results on Oct 29, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2025 results on Oct 29, 2025
Major Estimate Revision • Aug 27Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥23.6b to CN¥22.5b. EPS estimate also fell from CN¥1.08 per share to CN¥0.961 per share. Net income forecast to grow 73% next year vs 60% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥23.04 to CN¥22.26. Share price fell 2.9% to CN¥18.18 over the past week.
Major Estimate Revision • Jul 11Consensus revenue estimates decrease by 11%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥23.6b to CN¥21.0b. EPS estimate increased from CN¥1.05 to CN¥1.08 per share. Net income forecast to grow 68% next year vs 68% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥23.77. Share price fell 3.7% to CN¥19.34 over the past week.
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (2.0% net profit margin).
お知らせ • Jun 30LBX Pharmacy Chain Joint Stock Company to Report First Half, 2025 Results on Aug 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2025 results on Aug 30, 2025
お知らせ • Jun 09LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China
Reported Earnings • May 01Full year 2024 earnings released: EPS: CN¥0.68 (vs CN¥1.22 in FY 2023)Full year 2024 results: EPS: CN¥0.68 (down from CN¥1.22 in FY 2023). Revenue: CN¥22.4b (flat on FY 2023). Net income: CN¥519.1m (down 44% from FY 2023). Profit margin: 2.3% (down from 4.1% in FY 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
お知らせ • Mar 28LBX Pharmacy Chain Joint Stock Company to Report Q1, 2025 Results on Apr 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2025 results on Apr 30, 2025
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥19.24, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 4.4% over the past three years.
お知らせ • Dec 27LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2024 results on Apr 30, 2025
分析記事 • Dec 24Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Major Estimate Revision • Dec 10Consensus EPS estimates increase by 13%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.17 to CN¥1.31. Revenue forecast steady at CN¥22.8b. Net income forecast to grow 23% next year vs 44% growth forecast for Consumer Retailing industry in China. Consensus price target up from CN¥25.50 to CN¥26.24. Share price was steady at CN¥18.98 over the past week.
分析記事 • Nov 06We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster EarningsLBX Pharmacy Chain Joint Stock Company's ( SHSE:603883 ) stock was strong despite it releasing a soft earnings report...
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥19.25, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 23% over the past three years.
Reported Earnings • Oct 30Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.26 in 3Q 2023). Revenue: CN¥5.29b (up 1.2% from 3Q 2023). Net income: CN¥127.4m (down 37% from 3Q 2023). Profit margin: 2.4% (down from 3.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Oct 03Upcoming dividend of CN¥0.33 per shareEligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.9%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.9%).
お知らせ • Sep 30LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2024 results on Oct 30, 2024
Price Target Changed • Sep 20Price target decreased by 12% to CN¥26.64Down from CN¥30.14, the current price target is an average from 11 analysts. New target price is 88% above last closing price of CN¥14.18. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥1.43 for next year compared to CN¥1.22 last year.
Valuation Update With 7 Day Price Move • Sep 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥13.28, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Consumer Retailing industry in China. Total loss to shareholders of 48% over the past three years.
Major Estimate Revision • Sep 07Consensus EPS estimates fall by 29%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥26.0b to CN¥23.6b. EPS estimate also fell from CN¥2.08 per share to CN¥1.49 per share. Net income forecast to grow 6.3% next year vs 56% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥31.93 to CN¥30.14. Share price rose 33% to CN¥17.92 over the past week.
分析記事 • Sep 06LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%LBX Pharmacy Chain Joint Stock Company ( SHSE:603883 ) shareholders are no doubt pleased to see that the share price...
New Risk • Sep 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change).
Valuation Update With 7 Day Price Move • Sep 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Consumer Retailing industry in China. Total loss to shareholders of 46% over the past three years.
Buy Or Sell Opportunity • Sep 02Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 53% to CN¥12.24. The fair value is estimated to be CN¥15.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 9.8%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.
分析記事 • Sep 02Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Jul 03Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% CheaperThe LBX Pharmacy Chain Joint Stock Company ( SHSE:603883 ) share price has fared very poorly over the last month...
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥18.36, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 17x in the Consumer Retailing industry in China. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.59 per share.
お知らせ • Jun 28LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2024 results on Aug 30, 2024
Declared Dividend • Jun 23Dividend increased to CN¥0.66Dividend of CN¥0.66 is 32% higher than last year. Ex-date: 27th June 2024 Payment date: 27th June 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 19% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 65% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Jun 08Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
お知らせ • May 24LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024, at 14:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China
分析記事 • May 21LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Apr 30Full year 2023 earnings: EPS in line with expectations, revenues disappointFull year 2023 results: EPS: CN¥1.59 (up from CN¥1.36 in FY 2022). Revenue: CN¥22.4b (up 11% from FY 2022). Net income: CN¥929.0m (up 18% from FY 2022). Profit margin: 4.1% (up from 3.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
分析記事 • Apr 22There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is UndemandingLBX Pharmacy Chain Joint Stock Company's ( SHSE:603883 ) price-to-earnings (or "P/E") ratio of 20.9x might make it look...
お知らせ • Mar 29LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2024 results on Apr 30, 2024
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥31.93, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Consumer Retailing industry in China. Total loss to shareholders of 45% over the past three years.
お知らせ • Dec 29LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2023 results on Apr 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.26 in 3Q 2022). Revenue: CN¥5.23b (up 9.3% from 3Q 2022). Net income: CN¥203.3m (up 33% from 3Q 2022). Profit margin: 3.9% (up from 3.2% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 05Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: CN¥0.38. Revenue: CN¥5.37b (up 11% from 2Q 2022). Net income: CN¥221.9m (up 3.4% from 2Q 2022). Profit margin: 4.1% (down from 4.4% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China.
Reported Earnings • Apr 29Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)Full year 2022 results: EPS: CN¥1.36 (up from CN¥1.26 in FY 2021). Revenue: CN¥20.2b (up 28% from FY 2021). Net income: CN¥785.0m (up 17% from FY 2021). Profit margin: 3.9% (down from 4.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Buying Opportunity • Apr 19Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.
Price Target Changed • Apr 03Price target increased by 8.1% to CN¥45.36Up from CN¥41.97, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CN¥34.65. Stock is up 24% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year.
Buying Opportunity • Apr 03Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 44% in 2 years. Earnings is forecast to grow by 52% in the next 2 years.
Price Target Changed • Feb 03Price target increased by 7.5% to CN¥43.11Up from CN¥40.10, the current price target is an average from 7 analysts. New target price is 12% above last closing price of CN¥38.45. Stock is up 18% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year.
Price Target Changed • Jan 14Price target increased to CN¥41.97Up from CN¥39.10, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of CN¥42.00. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥1.39 for next year compared to CN¥1.26 last year.
Buying Opportunity • Dec 22Now 22% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be CN¥48.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 43% in 2 years. Earnings is forecast to grow by 51% in the next 2 years.
Buying Opportunity • Dec 06Now 21% undervaluedOver the last 90 days, the stock is up 28%. The fair value is estimated to be CN¥52.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 42% in 2 years. Earnings is forecast to grow by 51% in the next 2 years.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Lianfeng Wu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2021). Revenue: CN¥4.79b (up 25% from 3Q 2021). Net income: CN¥153.1m (up 21% from 3Q 2021). Profit margin: 3.2% (down from 3.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥33.36, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total loss to shareholders of 21% over the past three years.
Price Target Changed • May 21Price target decreased to CN¥58.58Down from CN¥63.49, the current price target is an average from 11 analysts. New target price is 61% above last closing price of CN¥36.32. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥1.86 for next year compared to CN¥1.64 last year.
Major Estimate Revision • May 05Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥19.5b to CN¥18.5b. EPS estimate also fell from CN¥2.04 per share to CN¥1.61 per share. Net income forecast to grow 21% next year vs 30% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥63.49 to CN¥59.92. Share price rose 10.0% to CN¥32.24 over the past week.
Reported Earnings • Apr 30First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: CN¥0.53. Revenue: CN¥4.14b (up 14% from 1Q 2021). Net income: CN¥241.8m (up 6.3% from 1Q 2021). Profit margin: 5.8% (down from 6.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 22%, compared to a 16% growth forecast for the industry in China.
Price Target Changed • Apr 27Price target decreased to CN¥63.49Down from CN¥81.75, the current price target is an average from 8 analysts. New target price is 112% above last closing price of CN¥29.90. Stock is down 47% over the past year. The company is forecast to post earnings per share of CN¥1.70 for next year compared to CN¥1.54 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Yang Haiyu was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥3.82b (up 11% from 3Q 2020). Net income: CN¥126.8m (down 16% from 3Q 2020). Profit margin: 3.3% (down from 4.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 26LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion on August 24, 2021. Under the terms of consideration, The first advance payment: within 7 working days after this agreement is signed and effective, 20% of the total transfer price shall be paid, totaling CNY 285.6 million and The second transfer price: After the completion of the target company’s assets divestiture, the target equity change, the establishment of the target company’s board of directors, and the completion of the above work within seven working days, 40% of the total transfer price shall be paid, totaling CNY 571.2 million and The third transfer payment: 10% of the total transfer price shall be paid within 7 working days after the establishment of the board of directors, totaling CNY 142.8 million and The fourth transfer price: within 7 working days after the seller provides the personal income tax payment voucher, 10% of the total transfer price shall be paid, totaling CNY 142.8 million and The fifth transfer price: After auditing, evaluating and confirming that the net assets of the target company meet stipulated in this agreement on the delivery date, within 7 working days 10% of the total transfer price shall be paid, totaling RMB 142.8 million and The sixth transfer price: the amount of CNY 142.8 million yuan is the deposit, and the guarantee period is one year (calculated from the delivery date). After the expiration, the two parties confirm that the seller has no deductions for payment and shall pay within 7 working days. The consideration will be funded through its own funds. Hebei Hua Tuo Pharmacy Medicine Chain reported total assets of CNY 821.6 million and total common equity of CNY 227.7 million till April 31, 2021. LBX Pharmacy Chain Joint Stock Company's board approved the deal.
Price Target Changed • Aug 20Price target decreased to CN¥75.25Down from CN¥81.75, the current price target is an average from 7 analysts. New target price is 53% above last closing price of CN¥49.27. Stock is down 36% over the past year.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.82b (up 12% from 2Q 2020). Net income: CN¥178.3m (up 28% from 2Q 2020). Profit margin: 4.7% (up from 4.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Aug 14Price target decreased to CN¥79.67Down from CN¥86.50, the current price target is an average from 6 analysts. New target price is 65% above last closing price of CN¥48.28. Stock is down 31% over the past year.
Price Target Changed • Jun 16Price target decreased to CN¥86.50Down from CN¥93.56, the current price target is an average from 7 analysts. New target price is 61% above last closing price of CN¥53.65. Stock is down 20% over the past year.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.64b (up 11% from 1Q 2020). Net income: CN¥227.5m (up 16% from 1Q 2020). Profit margin: 6.3% (up from 6.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 09New 90-day low: CN¥61.85The company is down 10.0% from its price of CN¥68.36 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥48.82 per share.
お知らせ • Feb 09Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership).Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) entered into an agreement to acquire Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) for CNY 680 million on December 18, 2020. As part of the transaction, Laobaixing Pharmacy Chain will pay CNY 20.4 million, CNY 20.6 million and CNY 27 million to Shanghai Chengzhen Enterprise Management Partnership, Shanghai Boyi Enterprise Management Consulting Service and Shanghai Xinzhen Marketing Planning Service Center, respectively. Laobaixing Pharmacy Chain will pay CNY 136 million within 7 working days after the signing of this agreement, CNY 476 million within seven working days after the completion of the settlement and the balance of CNY 68 million within seven working days of the settlement of related party's corresponding borrowings. The Board of Directors of Laobaixing Pharmacy Chain approved the transaction and no need to submit it to the general meeting of shareholders for review. Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) on February 8, 2020. Laobaixing Pharmacy Chain used own funds of CNY 680 million to acquire Jinan Xincheng Enterprise Management.
Is New 90 Day High Low • Jan 13New 90-day high: CN¥81.64The company is up 1.0% from its price of CN¥80.70 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥78.46, the stock is trading at a trailing P/E ratio of 53.3x, up from the previous P/E ratio of 45.3x. This compares to an average P/E of 32x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 84%.
Is New 90 Day High Low • Dec 28New 90-day low: CN¥63.60The company is down 22% from its price of CN¥81.13 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.
Is New 90 Day High Low • Dec 12New 90-day low: CN¥65.89The company is down 19% from its price of CN¥81.54 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share.
Is New 90 Day High Low • Nov 18New 90-day low: CN¥67.21The company is down 8.0% from its price of CN¥73.07 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥53.67 per share.
Price Target Changed • Nov 18Price target raised to CN¥97.98Up from CN¥89.75, the current price target is an average from 8 analysts. The new target price is 46% above the current share price of CN¥67.21. As of last close, the stock is up 33% over the past year.
お知らせ • Nov 05Laobaixing Reportedly in Merger Talks with YixintangLaobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) and Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) are in advanced talks to create China’s biggest drugstore chain via a share swap, three people familiar with the matter said. Laobaixing’s founders, Xie Zilong and Chen Xiulan, are expected to have a bigger stake in the merged firm than Yixintang’s founder Ruan Hongxian, said two of the people. The talks have been ongoing for more than three months, the two people said. One person said the firms are aiming to finalize and announce the deal in the coming days, adding that Laobaixing would remain the listed entity. The sources declined to be identified as the discussions were not public. Laobaixing, Yixintang did not immediately respond to requests for comment yesterday.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥601.8m, up 19% from the prior year. Total revenue was CN¥13.4b over the last 12 months, up 21% from the prior year.
お知らせ • Oct 30Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020Laobaixing Pharmacy Chain Joint Stock Company announced that they will report Q3, 2020 results on Oct 30, 2020
お知らせ • Jul 09Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020Laobaixing Pharmacy Chain Joint Stock Company announced that they will report first half, 2020 results on Aug 21, 2020
